{"id":27535,"date":"2022-05-11T17:11:07","date_gmt":"2022-05-11T12:11:07","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=91577"},"modified":"2022-05-11T17:11:07","modified_gmt":"2022-05-11T12:11:07","slug":"ena-respiratory-selected-for-blue-knight-to-accelerate-development-of-pan-antiviral-nasal-spray","status":"publish","type":"post","link":"https:\/\/myanmarnewsgazette.com\/ena-respiratory-selected-for-blue-knight-to-accelerate-development-of-pan-antiviral-nasal-spray\/","title":{"rendered":"ENA Respiratory Selected for BLUE KNIGHT\u2122 to Accelerate Development of Pan-Antiviral Nasal Spray"},"content":{"rendered":"
\n

SYDNEY, Australia, May 11, 2022 (GLOBE NEWSWIRE) — ENA Respiratory<\/a>, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pan-antiviral prophylaxis in at-risk populations and pandemic preparedness, has been selected to join BLUE KNIGHT\u2122<\/a>, a joint initiative between Johnson & Johnson Innovation \u2013 JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA), a component of the U.S. Department of Health and Human Services. ENA Respiratory is the first Australian company to be selected to join Blue Knight<\/strong>.<\/p>\n

Blue Knight<\/strong> offers a scientific and technological ecosystem for innovative, early-stage companies to develop strategically aligned technologies that aim to combat health threats and emerging infectious diseases. ENA Respiratory\u2019s selection highlights the urgent unmet need for therapies that could help the body respond faster to a broad range of respiratory viral infections and reduce the risk of hospitalization or complications. As a Blue Knight<\/strong> company, ENA Respiratory will benefit from mentorship from experts from BARDA, the Johnson & Johnson Family of Companies, and a global network of innovators who could provide critical insight and support throughout INNA-051 development.<\/p>\n

ENA Respiratory\u2019s self-administered nasal spray INNA-051 product is designed with the aim to stimulate the innate immunity in the nose, which is the preferential site of initial infection and replication of most respiratory viruses. Pre-clinical research demonstrates that INNA-051 has pan-antiviral potential with efficacy against a variety of respiratory viruses, including SARS-CoV-2, influenza, and the common cold rhinovirus.<\/p>\n

\u201cAs we continue to advance the development of INNA-051, we look forward to working alongside BARDA, industry leaders, and other innovative companies with the aim to address emerging health threats and better protect our global community against infectious diseases,\u201d said Christophe Demaison, Ph.D., CEO of ENA Respiratory.<\/p>\n

ENA Respiratory is a virtual resident within JLABS<\/a>, a premier life science incubator program.<\/p>\n

Recently, ENA Respiratory began a Phase 2a influenza challenge pre-exposure prophylaxis study of INNA-051. It was found to be well-tolerated in a Phase 1 study, and Phase 1 data will be presented at the 2022 American Thoracic Society International Conference (May 13- 18, San Francisco).<\/p>\n

Notes to Editors <\/strong><\/p>\n

If you would like to arrange an interview, please contact:<\/p>\n